Long-term health management products, specifically chronic therapies, have been driving the growth of the Indian Pharmaceutical Market (IPM) with a 10% increase, in contrast to acute therapies which saw a 2% growth, showing a trend towards prolong...
The MHRA in the UK has given the approval to sparsentan (Filspari) for the treatment of IgAN. Berger's disease, or IgA neuropathy, is a kidney condition caused by the accumulation of immunoglobulin A (IgA) antibodies in the kidneys. Sparsentan...
Anti-diabetics and cardiac treatments are the main drivers of the domestic pharmaceutical market, with respiratory treatments projected to be the primary growth drivers in November, December, and January. With air pollution persisting, it is...
Glenmark became the first Indian company to introduce a biosimilar of the anti-diabetic GLP-1 drug Liraglutide in India. Additionally, it has revealed a number of collaborations to introduce new drugs, such as partnerships with Jiangsu Alphamab...
The exclusive license agreement permits Pharmanovia to launch catumaxomab, a unique trifunctional bi-specific monoclonal antibody, for intraperitoneal treatment of malignant ascites in EpCAM-positive carcinoma patients ineligible for additional...
The United States continues to be a crucial market for the Indian pharmaceutical industry, representing approximately 30% of overall sales and capturing a 40% share of the market in terms of volume. Despite possible risks from changes in duty...
There is a noticeable shift towards smart packaging technologies in the pharmaceutical blister packaging market. The trend of incorporating digital functions like tracking products using smartphones and reminding patients to take medication on...
China is upgrading its pharmaceutical industry to make drugs and healthcare more accessible. This is part of its plan to become more self-reliant through “new quality productive forces” driven by technical innovation and a supportive business...
Strengthening of Pharmaceutical Industry (SPI)' initiative, backed by Rs 500 crore (USD 60.9 million) provides vital support to enhance productivity, quality and sustainability across pharma clusters and MSMEs nationwide....
India holds the biggest share in global generic medicine supply with 20 percent, producing 60,000 generic brands in 60 therapeutic categories. Products made in the country are sent to more than 200 countries worldwide, with Japan, Australia...
, CDSCO.jpg)
